Zealand Pharma A/S/ DK0060257814 /
2024-09-06 4:53:01 PM | Chg. +4.00 | Volume | Bid2024-07-19 | Ask2024-07-19 | High | Low |
---|---|---|---|---|---|---|
825.50DKK | +0.49% | 1,101 Turnover: 915,454.50 |
-Bid Size: - | -Ask Size: - | 839.50 | 823.50 |
GlobeNewswire
08-22
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
GlobeNewswire
08-12
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial...
GlobeNewswire
06-26
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary share...
GlobeNewswire
06-25
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900...
GlobeNewswire
06-25
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 90...
GlobeNewswire
06-20
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose ...
GlobeNewswire
06-07
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...
GlobeNewswire
06-07
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...
GlobeNewswire
06-06
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...
GlobeNewswire
05-31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
05-29
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
GlobeNewswire
05-23
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...
GlobeNewswire
05-09
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire
03-20
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire
02-26
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire
02-26
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...